Media ReleasesChimeric Therapeutics

View All Chimeric Therapeutics News

Chimeric Therapeutics - CLTX CAR T presents positive initial Phase 1 clinical data

• 75% disease control rate seen at lowest dose level of CLTX CAR T cells
• CLTX CAR T was generally well tolerated with no dose limiting toxicities
• Persistence of CLTX CAR T cells shown throughout treatment
• Results give Chimeric confidence as higher dose levels and dual routes of administration commence
• Webinar to be held at 9:30am AEDT today discussing the results. Click here to register.

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and the ASX leader in cell therapy, is pleased to highlight the release of two CLTX CAR T abstracts for presentation at the Society for Neuro-Oncology (SNO) 27th annual scientific meeting which have shown positive results from Chimeric’s CLTX CAR T phase 1 clinical trial.

Abstract CTIM-29, “Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastoma” provides insight into the initial clinical data for CLTX while abstract EXTH-10, “Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognize glioblastoma cells?” expands on the translational understanding of Chlorotoxin (CLTX) activity.

The clinical data released in abstract CTIM-29 is from the ongoing CLTX CAR T phase 1 clinical trial in patients with MMP2+ recurrent or progressive glioblastoma. The data focuses on the four patients enrolled in dose level 1 of the trial, treated with 44 X 106 CLTX CAR T cells through a single route of intratumoral administration. Dose escalation in this trial is planned across four dose levels to a total dose of 440 X 106 CLTX CAR T cells administered through dual intratumoral and intraventricular routes of administration.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.